AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33840229 — intervention group
Group type: EXPERIMENTAL
Intervention: Benralizumab (both dosing regimens)
Number of subjects: 56
Study 33840229 — intervention group
Group type: EXPERIMENTAL
Intervention: Benralizumab (in patients with high blood eosinophil levels)
Number of subjects: 56
Study 32275368 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture combined with conventional symptomatic and supportive treatments
Number of subjects: 68
Study 32275368 — intervention group
Group type: COMPARATOR
Intervention: Symptomatic and supportive treatments (control group)
Number of subjects: 68
Study 35114800 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant intraperitoneal‐systemic chemotherapy
Number of subjects: 238
Study 35114800 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel + S‐1 (PS) chemotherapy
Number of subjects: 238
Study 33026517 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg ICG injection at 8 hours prior to surgery
Number of subjects: 29
Study 33026517 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg ICG injection at 10 hours prior to surgery
Number of subjects: 29
Study 33026517 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg ICG injection at 12 hours prior to surgery
Number of subjects: 29
Study 33026517 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg ICG injection at 14 hours prior to surgery
Number of subjects: 29
Study 36364825 — intervention group
Group type: EXPERIMENTAL
Intervention: Live Lactobacillus paracasei (L-PS23, 2 × 10^10 CFU/day)
Number of subjects: 0
Study 36364825 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat-killed Lactobacillus paracasei (HK-PS23, 2 × 10^10 cells/day)
Number of subjects: 0
Study 36364825 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 32997229 — intervention group
Group type: EXPERIMENTAL
Intervention: Social network density
Number of subjects: 94
Study 32997229 — intervention group
Group type: EXPERIMENTAL
Intervention: Social network size
Number of subjects: 94
Study 35442179 — intervention group
Group type: EXPERIMENTAL
Intervention: HCP Plus Peer Support
Number of subjects: 292
Study 35442179 — intervention group
Group type: COMPARATOR
Intervention: HCP Support
Number of subjects: 292
Study 32046568 — intervention group
Group type: EXPERIMENTAL
Intervention: High breath alcohol concentration (BAC) group (≥0.08)
Number of subjects: 137
Study 32046568 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate breath alcohol concentration (BAC) group (≤0.08)
Number of subjects: 137
Study 32046568 — intervention group
Group type: EXPERIMENTAL
Intervention: Sober group
Number of subjects: 137
Study 32046568 — intervention group
Group type: COMPARATOR
Intervention: Control condition (juice)
Number of subjects: 137
Study 32046568 — intervention group
Group type: EXPERIMENTAL
Intervention: High BAC group (≥0.08)
Number of subjects: 137
Study 32046568 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate BAC group (≤0.08)
Number of subjects: 137
Study 36044215 — intervention group
Group type: EXPERIMENTAL
Intervention: AI-aided interpretation
Number of subjects: 497
Study 33313808 — intervention group
Group type: EXPERIMENTAL
Intervention: Definitions retrieved from the Delphi-like method
Number of subjects: 30
Study 33313808 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-observer agreement for SU
Number of subjects: 30
Study 33313808 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-observer agreement for AE
Number of subjects: 30
Study 33313808 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-observer agreement for DU
Number of subjects: 30
Study 33313808 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-observer agreement for any ulceration (DU or SU)
Number of subjects: 30
Study 33313808 — intervention group
Group type: EXPERIMENTAL
Intervention: Inter-observer agreement for SU
Number of subjects: 30
Study 33313808 — intervention group
Group type: EXPERIMENTAL
Intervention: Inter-observer agreement for AE
Number of subjects: 30
Study 33313808 — intervention group
Group type: EXPERIMENTAL
Intervention: Inter-observer agreement for DU
Number of subjects: 30
Study 33313808 — intervention group
Group type: EXPERIMENTAL
Intervention: Inter-observer agreement for any ulceration
Number of subjects: 30
Study 33313808 — intervention group
Group type: EXPERIMENTAL
Intervention: Inter-observer agreement for high-quality videos (DU)
Number of subjects: 30
Study 33313808 — intervention group
Group type: EXPERIMENTAL
Intervention: Inter-observer agreement for high-quality videos (AE)
Number of subjects: 30
Study 33313808 — intervention group
Group type: EXPERIMENTAL
Intervention: Inter-observer agreement for high-quality videos (any ulceration)
Number of subjects: 30
Study 35235198 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention Group (IG): 40–45 kcal and 1.5 g protein/kg/day; diet plus polymeric formula
Number of subjects: 104
Study 34202877 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucosamine hydrochloride (3000 mg GlucosaGreen®)
Number of subjects: 11
Study 34202877 — intervention group
Group type: COMPARATOR
Intervention: Maltodextrin placebo
Number of subjects: 11
Study 32327366 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep dry needling
Number of subjects: 24
Study 32327366 — intervention group
Group type: COMPARATOR
Intervention: Sham dry needling
Number of subjects: 24
Study 35249488 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise intervention (60 minutes, three times per week for 16 weeks)
Number of subjects: 45
Study 35249488 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 45
Study 33691739 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep learning-based fully-automatic DENSE strain analysis
Number of subjects: 64
Study 33691739 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep learning-based phase unwrapping U-Net
Number of subjects: 64
Study 33691739 — intervention group
Group type: COMPARATOR
Intervention: Deep learning-based fully-automatic global and segmental circumferential strain analysis
Number of subjects: 64
Study 36424008 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofogliflozin (20 mg/d)
Number of subjects: 80
Study 36424008 — intervention group
Group type: COMPARATOR
Intervention: Anagliptin (200 mg/d)
Number of subjects: 80
Study 33940625 — intervention group
Group type: EXPERIMENTAL
Intervention: Total sleep deprivation
Number of subjects: 68
Study 33940625 — intervention group
Group type: COMPARATOR
Intervention: Well-rested control condition
Number of subjects: 68
Study 32172292 — intervention group
Group type: EXPERIMENTAL
Intervention: Constant learning
Number of subjects: 90
Study 32172292 — intervention group
Group type: EXPERIMENTAL
Intervention: Variable learning
Number of subjects: 90
Study 32172292 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 90
Study 34802140 — intervention group
Group type: EXPERIMENTAL
Intervention: Erector spinae plane block (ESPB)
Number of subjects: 78
Study 34802140 — intervention group
Group type: COMPARATOR
Intervention: Control group (no block)
Number of subjects: 78
Study 34895357 — intervention group
Group type: EXPERIMENTAL
Intervention: Integration of HIV risk screening and PrEP delivery in public health family planning clinics, delivered by existing FP clinic staff with training and technical assistance.
Number of subjects: 0
Study 34895357 — intervention group
Group type: EXPERIMENTAL
Intervention: Core multifaceted implementation strategies including health provider training and stakeholder engagement.
Number of subjects: 0
Study 34895357 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard care service package including screening for HIV risk, HIV testing, dispensing, adherence and risk reduction counseling, assessment of side effects, and provision of refills.
Number of subjects: 0
Study 34952965 — intervention group
Group type: EXPERIMENTAL
Intervention: Obturator Nerve Block (ONB)
Number of subjects: 0
Study 32977221 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib
Number of subjects: 275
Study 32977221 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 275
Study 32977221 — intervention group
Group type: EXPERIMENTAL
Intervention: Independent-assessed RECIST
Number of subjects: 275
Study 36067615 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib (300 mg twice daily) plus bevacizumab (15 mg/kg every 3 weeks) for up to 24 months and 15 months respectively
Number of subjects: 0
Study 36067615 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus bevacizumab (15 mg/kg every 3 weeks) for up to 15 months
Number of subjects: 0
Study 36067615 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib (300 mg twice daily) plus bevacizumab (15 mg/kg every 3 weeks)
Number of subjects: 0
Study 36067615 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus bevacizumab (15 mg/kg every 3 weeks)
Number of subjects: 0
Study 33789008 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab (240 mg every 2 weeks for 16 weeks, followed by 480 mg every 4 weeks)
Number of subjects: 794
Study 33789008 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 794
Study 33789008 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 794
Study 35106400 — intervention group
Group type: EXPERIMENTAL
Intervention: Capacity-building intervention including a structured toolkit and technical-assistance calls
Number of subjects: 20
Study 35106400 — intervention group
Group type: COMPARATOR
Intervention: Control arm (no specific intervention mentioned)
Number of subjects: 20
Study 33336427 — intervention group
Group type: EXPERIMENTAL
Intervention: Effective supervision model implemented by the Ministry of Health and Population (MOHP) at central, governorate, and district levels.
Number of subjects: 500
Study 33336427 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized consistent checklist used by supervisors for service delivery.
Number of subjects: 500
Study 35584106 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibration Foam Roller (VFR)
Number of subjects: 0
Study 35584106 — intervention group
Group type: EXPERIMENTAL
Intervention: Portable Vibration Percussion Device (PVPD)
Number of subjects: 0
Study 35584106 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study 33542046 — intervention group
Group type: EXPERIMENTAL
Intervention: iSelf-help (online-delivered PMP)
Number of subjects: 180
Study 33542046 — intervention group
Group type: COMPARATOR
Intervention: In-person PMP (control group)
Number of subjects: 180
Study 35387943 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical intervention (clipping)
Number of subjects: 1863
Study 35387943 — intervention group
Group type: COMPARATOR
Intervention: Endovascular treatment (coiling)
Number of subjects: 1863
Study 33828257 — intervention group
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Number of subjects: 0
Study 33828257 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 32713850 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-directed multimedia consent process
Number of subjects: 298
Study 32713850 — intervention group
Group type: COMPARATOR
Intervention: Traditional paper-based consent process
Number of subjects: 298
Study 34969541 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholvax (Incepta Vaccine Ltd)
Number of subjects: 2052
Study 33026142 — intervention group
Group type: EXPERIMENTAL
Intervention: Short acting BP medication added in the evening
Number of subjects: 33
Study 33026142 — intervention group
Group type: COMPARATOR
Intervention: No medication change (control)
Number of subjects: 33
Study 35236080 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine
Number of subjects: 0
Study 35236080 — intervention group
Group type: COMPARATOR
Intervention: 5-Fluorouracil (5-FU)
Number of subjects: 0
Study 33024323 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrin glue (FG)‐assisted mucous membrane grafting (MMG)
Number of subjects: 20
Study 33024323 — intervention group
Group type: COMPARATOR
Intervention: Continuous 8‐0 polygalactin suture (PS)‐assisted mucous membrane grafting (MMG)
Number of subjects: 20
Study 33263357 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician/Personal (PP) message
Number of subjects: 2007
Study 33263357 — intervention group
Group type: COMPARATOR
Intervention: Federal/Impersonal (FI) message
Number of subjects: 2007
Study 35255880 — intervention group
Group type: EXPERIMENTAL
Intervention: Barberry (10 g/day dried barberry)
Number of subjects: 84
Study 34169420 — intervention group
Group type: EXPERIMENTAL
Intervention: Support Vector Regression (SVR) model
Number of subjects: 0
Study 34169420 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial Neural Network (ANN) model
Number of subjects: 0
Study 34169420 — intervention group
Group type: COMPARATOR
Intervention: Multiple Regression (MR) model
Number of subjects: 0
Study 32339447 — intervention group
Group type: EXPERIMENTAL
Intervention: hIL-7-hyFc (20, 60 μg/kg s.c. or 60 μg/kg i.m.)
Number of subjects: 30
Study 32339447 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 35867702 — intervention group
Group type: EXPERIMENTAL
Intervention: PegIFN alfa‐2a (180 μg/week) for 48 weeks
Number of subjects: 149
Study 35867702 — intervention group
Group type: COMPARATOR
Intervention: Nucleos(t)ide analogue (NA) for 48 weeks
Number of subjects: 149
Study 33561041 — intervention group
Group type: EXPERIMENTAL
Intervention: Forest Therapy (FT) intervention
Number of subjects: 140
Study 33561041 — intervention group
Group type: COMPARATOR
Intervention: Control period (10 weeks)
Number of subjects: 140
Study 34184165 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate loading (IL)
Number of subjects: 19
Study 34184165 — intervention group
Group type: COMPARATOR
Intervention: Conventional loading (CL)
Number of subjects: 19
Study 34184165 — intervention group
Group type: EXPERIMENTAL
Intervention: Both IL and CL groups
Number of subjects: 19
Study 32930112 — intervention group
Group type: EXPERIMENTAL
Intervention: TTF-1 positive patients
Number of subjects: 200
Study 32930112 — intervention group
Group type: EXPERIMENTAL
Intervention: TTF-1 negative patients
Number of subjects: 200
Study 32930112 — intervention group
Group type: EXPERIMENTAL
Intervention: TTF-1 negative with EGFR mutation positive
Number of subjects: 200
Study 32930112 — intervention group
Group type: EXPERIMENTAL
Intervention: TTF-1 negative with CK7 positive
Number of subjects: 200
Study 32930112 — intervention group
Group type: EXPERIMENTAL
Intervention: TTF-1 negative patients who received curative radiotherapy
Number of subjects: 200
Study 32930112 — intervention group
Group type: EXPERIMENTAL
Intervention: TTF-1 expression
Number of subjects: 200
Study 35849276 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous magnesium sulfate at a dose of 250 mg/kg (at 8 mg/kg/min) once daily for 3 days along with therapeutic hypothermia
Number of subjects: 134
Study 35849276 — intervention group
Group type: COMPARATOR
Intervention: Therapeutic hypothermia alone
Number of subjects: 134
Study 35849276 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous magnesium sulfate and therapeutic hypothermia
Number of subjects: 134
Study 35849276 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary outcomes including neonatal mortality, major neurodevelopmental disability at 1 y of age, neurological status at discharge, level of oxidative stress markers, and adverse effects
Number of subjects: 134
Study 34670201 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous theta burst stimulation (cTBS) administered over one of three stimulation targets in randomized order.
Number of subjects: 24
Study 34670201 — intervention group
Group type: EXPERIMENTAL
Intervention: Single administrations of cTBS over each target.
Number of subjects: 24
Study 35979351 — intervention group
Group type: EXPERIMENTAL
Intervention: Belimumab treatment
Number of subjects: 82
Study 35979351 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatments (historical controls)
Number of subjects: 82
Study 32650730 — intervention group
Group type: EXPERIMENTAL
Intervention: CT scan findings showing increased interstitial markings
Number of subjects: 360
Study 32650730 — intervention group
Group type: EXPERIMENTAL
Intervention: CT scan findings showing ground glass opacities
Number of subjects: 360
Study 32650730 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiologist's impression of PJP being possible
Number of subjects: 360
Study 32650730 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiologist's impression of PJP being likely
Number of subjects: 360
Study 32650730 — intervention group
Group type: COMPARATOR
Intervention: Chest x-ray findings
Number of subjects: 360
Study 34995162 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealth interventions for HIV prevention and treatment
Number of subjects: 0
Study 34995162 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote adaptations to behavioral interventions for HIV prevention
Number of subjects: 0
Study 34050628 — intervention group
Group type: EXPERIMENTAL
Intervention: Active bait boxes containing fipronil wick
Number of subjects: 622
Study 34050628 — intervention group
Group type: COMPARATOR
Intervention: Placebo bait boxes (empty)
Number of subjects: 622
Study 32157631 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-Brain Radiotherapy (WBRT)
Number of subjects: 0
Study 32157631 — intervention group
Group type: EXPERIMENTAL
Intervention: Hippocampal-Avoidant Whole-Brain Radiotherapy (HA-WBRT)
Number of subjects: 0
Study 32157631 — intervention group
Group type: COMPARATOR
Intervention: Stereotactic Radiosurgery (SRS) or Surgery Alone
Number of subjects: 0
Study 33326179 — intervention group
Group type: EXPERIMENTAL
Intervention: Aflibercept (2.0 mg/50 µl)
Number of subjects: 38
Study 33326179 — intervention group
Group type: COMPARATOR
Intervention: Ranibizumab (0.5 mg/50 µl)
Number of subjects: 38
Study 36322102 — intervention group
Group type: EXPERIMENTAL
Intervention: Resection plus permanent implantation of a novel radiation device utilizing the gamma‐emitting isotope Cs‐131 embedded within bioresorbable collagen tiles
Number of subjects: 28
Study 33859173 — intervention group
Group type: EXPERIMENTAL
Intervention: INTACT (Intact protein-based formula)
Number of subjects: 35
Study 33859173 — intervention group
Group type: EXPERIMENTAL
Intervention: PHw (Partially hydrolyzed whey-based formula)
Number of subjects: 35
Study 33859173 — intervention group
Group type: EXPERIMENTAL
Intervention: HPPHw (High-protein partially hydrolyzed whey-based formula)
Number of subjects: 35
Study 33859173 — intervention group
Group type: COMPARATOR
Intervention: HM (Human milk)
Number of subjects: 35
Study 32663660 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged anticoagulation (intravenous unfractionated heparin, subcutaneous enoxaparin, or intravenous bivalirudin) for at least 48 hours after pPCI
Number of subjects: 2856
Study 32663660 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo (no anticoagulation) for at least 48 hours after pPCI
Number of subjects: 2856
Study 32663660 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged anticoagulation
Number of subjects: 2856
Study 32663660 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 2856
Study 36501211 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein and pomegranate extract (Test group)
Number of subjects: 30
Study 36501211 — intervention group
Group type: COMPARATOR
Intervention: Protein and maltodextrin (Control group)
Number of subjects: 30
Study 32182276 — intervention group
Group type: EXPERIMENTAL
Intervention: Open condition (advance information about pitch type)
Number of subjects: 26
Study 32182276 — intervention group
Group type: COMPARATOR
Intervention: Random condition (no advance information about pitch type)
Number of subjects: 26
Study 32182276 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuity condition (same pitch type thrown consecutively)
Number of subjects: 26
Study 35551533 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal hormone-free moisturising cream
Number of subjects: 172
Study 35551533 — intervention group
Group type: COMPARATOR
Intervention: Vaginal estriol (0.1%) cream
Number of subjects: 172
Study 32897015 — intervention group
Group type: EXPERIMENTAL
Intervention: Nefradoz (150 mg, 2 times a day for 28-30 days)
Number of subjects: 60
Study 32897015 — intervention group
Group type: COMPARATOR
Intervention: Control group (general recommendations and standard diet therapy for 28-30 days)
Number of subjects: 60
Study 34371810 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcumin (HydroCurcTM; 500 mg) with low dose iron (18 mg)
Number of subjects: 155
Study 34371810 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcumin (HydroCurcTM; 500 mg) with high dose iron (65 mg)
Number of subjects: 155
Study 34371810 — intervention group
Group type: COMPARATOR
Intervention: Low dose iron (18 mg) with curcumin placebo
Number of subjects: 155
Study 34371810 — intervention group
Group type: COMPARATOR
Intervention: High dose iron (65 mg) with curcumin placebo
Number of subjects: 155
Study 32395901 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep neuromuscular block reversed with sugammadex
Number of subjects: 350
Study 32395901 — intervention group
Group type: COMPARATOR
Intervention: Moderate neuromuscular block reversed with neostigmine
Number of subjects: 350
Study 35397622 — intervention group
Group type: EXPERIMENTAL
Intervention: 90 g/day low-carbohydrate diet (LCD)
Number of subjects: 85
Study 35397622 — intervention group
Group type: COMPARATOR
Intervention: TDD (control group)
Number of subjects: 85
Study 33832346 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoropyrimidine (FP) therapy
Number of subjects: 102
Study 33298565 — intervention group
Group type: EXPERIMENTAL
Intervention: rAAV2/2‐ND4 (GS010)
Number of subjects: 37
Study 33298565 — intervention group
Group type: COMPARATOR
Intervention: Sham injection
Number of subjects: 37
Study 33298565 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (rAAV2/2‐ND4 and sham)
Number of subjects: 37
Study 35816053 — intervention group
Group type: EXPERIMENTAL
Intervention: BNT162b2 as second dose
Number of subjects: 210
Study 35816053 — intervention group
Group type: EXPERIMENTAL
Intervention: ChAdOx1 nCoV‐19 as second dose
Number of subjects: 210
Study 35816053 — intervention group
Group type: EXPERIMENTAL
Intervention: CoronaVac as second dose
Number of subjects: 210
Study 35816053 — intervention group
Group type: EXPERIMENTAL
Intervention: BNT162b2 booster after heterologous CoronaVac and ChAdOx1 nCoV‐19
Number of subjects: 210
Study 35816053 — intervention group
Group type: EXPERIMENTAL
Intervention: Heterologous two-dose schedules
Number of subjects: 210
Study 33628086 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugammadex 4 mg/kg
Number of subjects: 60
Study 33628086 — intervention group
Group type: COMPARATOR
Intervention: Pyridostigmine 0.15 mg/kg + glycopyrrolate 0.4 mg (control group)
Number of subjects: 60